Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20230206007
TCTR20230206007
Unknown
Not Applicable

Risk factors of osteonecrosis of the jaw in patients with multiple myeloma receiving intravenous bisphosphonates: Retrospective study

Chulalongkorn University0 sites120 target enrollmentFebruary 6, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPatients diagnosed with multiple myeloma and had received intravenous bisphosphonates.Risk factor, Multiple myeloma, Intravenous bisphosphonate

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Patients diagnosed with multiple myeloma and had received intravenous bisphosphonates.
Sponsor
Chulalongkorn University
Enrollment
120
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 6, 2023
End Date
April 28, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Patients diagnosed with multiple myeloma received intravenous bisphosphonates.
  • •2\.Patients who evaluate and/or treated as a new case or relapse of multiple myeloma.

Exclusion Criteria

  • •1\.Patients had a history of radiation therapy to the jaws or of tumors or cysts.
  • •2\.Undergoing a radiation therapy in the head and neck region
  • •3\.Patients had a history of osteonecrosis of the jaw before treating multiple myeloma with IV bisphosphonate.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic CancerBone DiseasesMetastasesOsteonecrosisBisphosphonate-Associated Osteonecrosis of the Jaw
NCT01325142University of Michigan271
Completed
Not Applicable
CONDOR Study of Osteonecrosis of the Jaws (TMJ)Osteonecrosis of the Jaw
NCT01130389Dental Practice-Based Research Network309
Completed
Not Applicable
Determination of risk factors for developing osteoporosis in COPD GOLD II patients. A case control study to identify possible risk factors for developing osteoporosis in COPD GOLD II patients.bone decalcification. AND chronic bronchitisemfysemaOsteoporosis1000595910006436
NL-OMON31334Catharina-ziekenhuis100
Completed
Not Applicable
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone MetastasesBreast CancerLung CancerMetastatic CancerMultiple MyelomaPlasma Cell NeoplasmProstate CancerUnspecified Adult Solid Tumor, Protocol Specific
NCT00874211SWOG Cancer Research Network3,571
Recruiting
Not Applicable
Prevention of drug-induced Bone Necrosis in the oral cavity in Cancer patients undergoing Tooth Removal – randomized clinical trialBisphosphonate-Associated Osteonecrosis of the JawC05.116.852
RBR-4zsh6g8Sociedade Pernambucana de Combate ao Câncer